Wilms tumour 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse

Br J Haematol. 2018 Jul;182(2):287-290. doi: 10.1111/bjh.14768. Epub 2017 May 23.

¹ Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Suita, Japan.
² Department of Haematology, Kitano Hospital, Osaka, Japan.
³ Department of Haematology, Nissay Hospital, Osaka, Japan.
⁴ Department of Infection Metagenomics, Genome Information Research Centre, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
⁵ Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Suita, Japan.
⁶ Department of Cancer Immunology, Osaka University Graduate School of Medicine, Suita, Japan.
⁷ Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine, Suita, Japan.
⁸ Department of Immunopathology, Immunology Frontier Research Centre (World Premier International Research Centre), Osaka University, Suita, Japan.

No abstract available

Keywords: Wilms tumor 1; acute myeloid leukaemia; immunotherapy.

Publication types